SLC34A2 and ovarian cancer: Antibodies were generated by immunizing mice with a combination of ovarian cancer tumor cells, and recognized NaPi2b on the cell surface of 80–90% of ovarian carcinoma tumors (Mattes et al., 1987; Welshinger et al., 1997).